Confirmatory molecular investigations for specific neoplasms are important for the use of targeted therapies such as BRAF or CDK4 inhibitors (in confirming that patients have melanoma rather than CCS and for patients with DDL, respectively) and for patient enrolment into appropriate clinical trials. This evidence concerns the gene CDK4 and neoplasm.